Published in Clin Liver Dis on November 01, 2006
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients | NCT03163849
The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl (2009) 1.64
The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol (2008) 1.46
Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem (2008) 1.32
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl (2012) 1.05
Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis (2014) 0.99
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther (2013) 0.92
The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One (2009) 0.91
Gaps in the hepatitis C continuum of care among sex workers in Vancouver, British Columbia: Implications for voluntary hepatitis C virus testing, treatment and care. Can J Gastroenterol Hepatol (2015) 0.90
Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis (2013) 0.88
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem (2011) 0.88
An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig (2015) 0.88
Innate immune evasion by hepatitis C virus and West Nile virus. Cytokine Growth Factor Rev (2007) 0.87
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol (2015) 0.86
SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85
Advances in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2012) 0.83
Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. Int J Organ Transplant Med (2016) 0.82
Donor diabetes mellitus is an independent risk factor for graft loss in HCV positive but not HCV negative liver transplant recipients. Dig Dis Sci (2012) 0.81
Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. Proc Natl Acad Sci U S A (2016) 0.80
Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol (2014) 0.80
TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. PLoS One (2015) 0.80
Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California. Dig Dis Sci (2013) 0.79
Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol (2013) 0.78
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. Curr Hepat Rep (2010) 0.78
Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure. J Clin Exp Hepatol (2016) 0.77
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLoS One (2015) 0.77
An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. AIDS Behav (2011) 0.77
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. BMC Gastroenterol (2015) 0.77
Recent advances in liver transplantation for the practicing gastroenterologist. Gastroenterol Hepatol (N Y) (2009) 0.76
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocr Rev (2015) 0.76
Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A Inhibitors. ACS Med Chem Lett (2016) 0.75
Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol (2015) 0.75
Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. Int J Prev Med (2014) 0.75
Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75
Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation. Dig Dis Sci (2017) 0.75
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology (2007) 3.40
Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology (2014) 3.29
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Clinical practice. Microscopic hematuria. N Engl J Med (2003) 2.96
Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg (2009) 2.95
A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. Am J Gastroenterol (2002) 2.75
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Steroid use in acute liver failure. Hepatology (2013) 2.23
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology (2011) 1.63
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology (2010) 1.60
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl (2003) 1.57
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology (2007) 1.56
Health-related quality of life and survival in liver transplant candidates. Liver Transpl (2010) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl (2013) 1.52
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Sorafenib: where do we go from here? Hepatology (2010) 1.38
Fistula first is not always the best strategy for the elderly. J Am Soc Nephrol (2013) 1.30
Living donor liver transplantation: summary of a conference at The National Institutes of Health. Liver Transpl (2002) 1.22
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl (2004) 1.19
Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol (2010) 1.17
The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant (2005) 1.16
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci (2012) 1.12
Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer (2010) 1.12
Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10
Point-of-care photomicroscopy of urine. N Engl J Med (2011) 1.09
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol (2009) 1.06
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol (2011) 1.06
Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation (2012) 1.03
Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci (2007) 1.03
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol (2007) 1.03
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol (2003) 1.02
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol (2005) 1.02
Hypothermic machine preservation attenuates ischemia/reperfusion markers after liver transplantation: preliminary results. J Surg Res (2010) 1.02
One-year morbidity after donor right hepatectomy. Liver Transpl (2004) 1.01
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol (2003) 0.95
Analysis of failure in living donor liver transplantation: differential outcomes in children and adults. World J Surg (2003) 0.95
Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation. Am J Transplant (2004) 0.95
Adult living donor liver transplantation. Am J Transplant (2004) 0.91
Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc (2011) 0.91
Cotton plants expressing a hemipteran-active Bacillus thuringiensis crystal protein impact the development and survival of Lygus hesperus (Hemiptera: Miridae) nymphs. J Econ Entomol (2012) 0.90
Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. Liver Transpl (2002) 0.89
Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology (2009) 0.89
Transplantation for alcoholic hepatitis--time to rethink the 6-month "rule". N Engl J Med (2011) 0.89
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl (2006) 0.88
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Discovery of diffuse biliary microhamartomas during liver procurement. Liver Transpl (2007) 0.88
Factors predicting failure of AV "fistula first" policy in the elderly. Hemodial Int (2013) 0.87
Has the time come to include urine dipstick testing in screening asymptomatic young adults? JAMA (2011) 0.87
Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. Liver Transpl (2003) 0.87
Evaluation of living liver donors. Prog Transplant (2003) 0.87
Predictors of candidate maturation among potential living donors. Am J Transplant (2005) 0.87
Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis (2008) 0.86
Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J Clin Gastroenterol (2011) 0.86
Obesity and microvascular invasion in hepatocellular carcinoma. Cancer Invest (2010) 0.85
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology (2002) 0.85
Disparities in arteriovenous fistula placement in older hemodialysis patients. Hemodial Int (2013) 0.85
Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol (2007) 0.85
Liver and intestine transplantation. Am J Transplant (2003) 0.83
Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest (2009) 0.83
Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation (2013) 0.83
Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol (2004) 0.83
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology (2014) 0.83
Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl (2012) 0.83
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl (2014) 0.82
Kidney and liver living donors: a comparison of experiences. Prog Transplant (2005) 0.82
Who should treat liver transplant patients? The transplant hepatologist or the gastroenterologist? Part I: the transplant hepatologist. J Hepatol (2006) 0.82
Characterization of the active site and insight into the binding mode of the anti-angiogenesis agent fumagillin to the manganese(II)-loaded methionyl aminopeptidase from Escherichia coli. J Biol Inorg Chem (2004) 0.82
Interpretation of liver chemistries in adult donors after living donor liver transplantation. J Clin Gastroenterol (2004) 0.82
The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk? Am J Kidney Dis (2012) 0.82
Live donor liver transplantation: current status. Curr Gastroenterol Rep (2008) 0.82
Smoking and hepatocellular carcinoma mortality. Exp Ther Med (2011) 0.81
Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. Am J Transplant (2002) 0.81
Use of Complementary and Alternative Medicine among Patients with End-Stage Renal Disease. Evid Based Complement Alternat Med (2013) 0.81
The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. Am J Gastroenterol (2005) 0.81
Microvascular hepatic artery anastomosis in pediatric segmental liver transplantation: microscope vs loupe. Transpl Int (2004) 0.80